🇺🇸 Ezetimibe/Rosuvastatin in United States
503 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 503
Most-reported reactions
- Acute Kidney Injury — 86 reports (17.1%)
- Myalgia — 70 reports (13.92%)
- Diarrhoea — 60 reports (11.93%)
- Off Label Use — 47 reports (9.34%)
- Anaemia — 45 reports (8.95%)
- Dyspnoea — 42 reports (8.35%)
- Asthenia — 39 reports (7.75%)
- Arthralgia — 38 reports (7.55%)
- Drug Interaction — 38 reports (7.55%)
- Nausea — 38 reports (7.55%)
Ezetimibe/Rosuvastatin in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Cardiovascular approved in United States
Frequently asked questions
Is Ezetimibe/Rosuvastatin approved in United States?
Ezetimibe/Rosuvastatin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Ezetimibe/Rosuvastatin in United States?
Addpharma Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.